This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to
the current therapy of pediatric patients age 1-24 months old with partial seizures. The
medication used in this study has been approved by FDA for the adjunctive treatment of
partial seizures in patients 2 years and older.